Here are the DEF 14A proxy statements from Tonix Pharmaceuticals Holding Corp. (TNXP) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow TNXP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TNXP filings page.
Tonix Pharmaceuticals Holding Corp. is asking shareholders to approve several key items at its 2026 virtual annual meeting. Investors will vote on electing nine directors, ratifying PwC as the new independent auditor, authorizing a flexible reverse stock split, and adopting a new 2026 stock incentive plan.
The Board seeks authority to implement one or more reverse stock splits over two years, at ratios between 1:2 and 1:250, to help maintain Nasdaq listing standards tied to minimum bid price. Shareholders of record on March 19, 2026, when 13,405,401 common shares were outstanding, may vote online or by proxy.